Cargando…
A circular network of coregulated sphingolipids dictates lung cancer growth and progression
BACKGROUND: Sphingolipid metabolism is among the top dysregulated pathways in non-small cell lung carcinomas (NSCLC). However, the molecular control of sphingolipid metabolic reprogramming in cancer progression remains unclear. METHODS: We first determined the correlation between sphingolipid metabo...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8047482/ https://www.ncbi.nlm.nih.gov/pubmed/33813137 http://dx.doi.org/10.1016/j.ebiom.2021.103301 |
_version_ | 1783679048502738944 |
---|---|
author | Meng, Qiong Hu, Xueting Zhao, Xinbao Kong, Xiangzhan Meng, Ya-Ming Chen, Yitian Su, Liangping Jiang, Xue Qiu, Xiaoyi Huang, Cheng Liu, Chao Wang, Minghui Wong, Ping-Pui |
author_facet | Meng, Qiong Hu, Xueting Zhao, Xinbao Kong, Xiangzhan Meng, Ya-Ming Chen, Yitian Su, Liangping Jiang, Xue Qiu, Xiaoyi Huang, Cheng Liu, Chao Wang, Minghui Wong, Ping-Pui |
author_sort | Meng, Qiong |
collection | PubMed |
description | BACKGROUND: Sphingolipid metabolism is among the top dysregulated pathways in non-small cell lung carcinomas (NSCLC). However, the molecular control of sphingolipid metabolic reprogramming in cancer progression remains unclear. METHODS: We first determined the correlation between sphingolipid metabolic gene expression and patient prognosis. We then carried out sphingolipidomics analysis of health individual and NSCLC patient sera as well as B3GNT5 and GAL3ST1 genetically perturbed NSCLC cell lines. We used these cell lines to perform tumorigenesis study to determine the cellular role of B3GNT5 and GAL3ST1 in cancer growth and progression. FINDINGS: The expression of B3GNT5 and GAL3ST1 among sphingolipid metabolic enzymes is most significantly associated with patient prognosis, whilst sphingolipidomics analysis of healthy individual and NSCLC patient sera identifies their metabolites, lacto/neolacto-series glycosphingolipid and sulfatide species, as potential biomarkers that were more effective than current clinical biomarkers for staging patients. Further network analysis of the sphingolipidomes reveals a circular network of coregulated sphingolipids, indicating that the lacto/neolacto-series glycosphingolipid/sulfatide balance functions as a checkpoint to determine sphingolipid metabolic reprograming during patient progression. Sphingolipidomics analysis of B3GNT5/GAL3ST1 genetically perturbed NSCLC cell lines confirms their key regulatory role in sphingolipid metabolism, while B3GNT5 and GAL3ST1 expression has an opposite role on tumorigenesis. INTERPRETATION: Our results provide new insights whereby B3GNT5 and GAL3ST1 differentially regulate sphingolipid metabolism in lung cancer growth and progression. FUNDING: This work was supported by the Natural Science Foundation of China (81872142, 81920108028); Guangzhou Science and Technology Program (201904020008); Guangdong Science and Technology Department (2020A0505100029, 2019A1515011802, 2020A1515011280, 2020B1212060018, 2020B1212030004); China Postdoctoral Science Foundation (2019M650226, 2019M650227). |
format | Online Article Text |
id | pubmed-8047482 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-80474822021-04-21 A circular network of coregulated sphingolipids dictates lung cancer growth and progression Meng, Qiong Hu, Xueting Zhao, Xinbao Kong, Xiangzhan Meng, Ya-Ming Chen, Yitian Su, Liangping Jiang, Xue Qiu, Xiaoyi Huang, Cheng Liu, Chao Wang, Minghui Wong, Ping-Pui EBioMedicine Research paper BACKGROUND: Sphingolipid metabolism is among the top dysregulated pathways in non-small cell lung carcinomas (NSCLC). However, the molecular control of sphingolipid metabolic reprogramming in cancer progression remains unclear. METHODS: We first determined the correlation between sphingolipid metabolic gene expression and patient prognosis. We then carried out sphingolipidomics analysis of health individual and NSCLC patient sera as well as B3GNT5 and GAL3ST1 genetically perturbed NSCLC cell lines. We used these cell lines to perform tumorigenesis study to determine the cellular role of B3GNT5 and GAL3ST1 in cancer growth and progression. FINDINGS: The expression of B3GNT5 and GAL3ST1 among sphingolipid metabolic enzymes is most significantly associated with patient prognosis, whilst sphingolipidomics analysis of healthy individual and NSCLC patient sera identifies their metabolites, lacto/neolacto-series glycosphingolipid and sulfatide species, as potential biomarkers that were more effective than current clinical biomarkers for staging patients. Further network analysis of the sphingolipidomes reveals a circular network of coregulated sphingolipids, indicating that the lacto/neolacto-series glycosphingolipid/sulfatide balance functions as a checkpoint to determine sphingolipid metabolic reprograming during patient progression. Sphingolipidomics analysis of B3GNT5/GAL3ST1 genetically perturbed NSCLC cell lines confirms their key regulatory role in sphingolipid metabolism, while B3GNT5 and GAL3ST1 expression has an opposite role on tumorigenesis. INTERPRETATION: Our results provide new insights whereby B3GNT5 and GAL3ST1 differentially regulate sphingolipid metabolism in lung cancer growth and progression. FUNDING: This work was supported by the Natural Science Foundation of China (81872142, 81920108028); Guangzhou Science and Technology Program (201904020008); Guangdong Science and Technology Department (2020A0505100029, 2019A1515011802, 2020A1515011280, 2020B1212060018, 2020B1212030004); China Postdoctoral Science Foundation (2019M650226, 2019M650227). Elsevier 2021-04-02 /pmc/articles/PMC8047482/ /pubmed/33813137 http://dx.doi.org/10.1016/j.ebiom.2021.103301 Text en © 2021 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Research paper Meng, Qiong Hu, Xueting Zhao, Xinbao Kong, Xiangzhan Meng, Ya-Ming Chen, Yitian Su, Liangping Jiang, Xue Qiu, Xiaoyi Huang, Cheng Liu, Chao Wang, Minghui Wong, Ping-Pui A circular network of coregulated sphingolipids dictates lung cancer growth and progression |
title | A circular network of coregulated sphingolipids dictates lung cancer growth and progression |
title_full | A circular network of coregulated sphingolipids dictates lung cancer growth and progression |
title_fullStr | A circular network of coregulated sphingolipids dictates lung cancer growth and progression |
title_full_unstemmed | A circular network of coregulated sphingolipids dictates lung cancer growth and progression |
title_short | A circular network of coregulated sphingolipids dictates lung cancer growth and progression |
title_sort | circular network of coregulated sphingolipids dictates lung cancer growth and progression |
topic | Research paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8047482/ https://www.ncbi.nlm.nih.gov/pubmed/33813137 http://dx.doi.org/10.1016/j.ebiom.2021.103301 |
work_keys_str_mv | AT mengqiong acircularnetworkofcoregulatedsphingolipidsdictateslungcancergrowthandprogression AT huxueting acircularnetworkofcoregulatedsphingolipidsdictateslungcancergrowthandprogression AT zhaoxinbao acircularnetworkofcoregulatedsphingolipidsdictateslungcancergrowthandprogression AT kongxiangzhan acircularnetworkofcoregulatedsphingolipidsdictateslungcancergrowthandprogression AT mengyaming acircularnetworkofcoregulatedsphingolipidsdictateslungcancergrowthandprogression AT chenyitian acircularnetworkofcoregulatedsphingolipidsdictateslungcancergrowthandprogression AT suliangping acircularnetworkofcoregulatedsphingolipidsdictateslungcancergrowthandprogression AT jiangxue acircularnetworkofcoregulatedsphingolipidsdictateslungcancergrowthandprogression AT qiuxiaoyi acircularnetworkofcoregulatedsphingolipidsdictateslungcancergrowthandprogression AT huangcheng acircularnetworkofcoregulatedsphingolipidsdictateslungcancergrowthandprogression AT liuchao acircularnetworkofcoregulatedsphingolipidsdictateslungcancergrowthandprogression AT wangminghui acircularnetworkofcoregulatedsphingolipidsdictateslungcancergrowthandprogression AT wongpingpui acircularnetworkofcoregulatedsphingolipidsdictateslungcancergrowthandprogression AT mengqiong circularnetworkofcoregulatedsphingolipidsdictateslungcancergrowthandprogression AT huxueting circularnetworkofcoregulatedsphingolipidsdictateslungcancergrowthandprogression AT zhaoxinbao circularnetworkofcoregulatedsphingolipidsdictateslungcancergrowthandprogression AT kongxiangzhan circularnetworkofcoregulatedsphingolipidsdictateslungcancergrowthandprogression AT mengyaming circularnetworkofcoregulatedsphingolipidsdictateslungcancergrowthandprogression AT chenyitian circularnetworkofcoregulatedsphingolipidsdictateslungcancergrowthandprogression AT suliangping circularnetworkofcoregulatedsphingolipidsdictateslungcancergrowthandprogression AT jiangxue circularnetworkofcoregulatedsphingolipidsdictateslungcancergrowthandprogression AT qiuxiaoyi circularnetworkofcoregulatedsphingolipidsdictateslungcancergrowthandprogression AT huangcheng circularnetworkofcoregulatedsphingolipidsdictateslungcancergrowthandprogression AT liuchao circularnetworkofcoregulatedsphingolipidsdictateslungcancergrowthandprogression AT wangminghui circularnetworkofcoregulatedsphingolipidsdictateslungcancergrowthandprogression AT wongpingpui circularnetworkofcoregulatedsphingolipidsdictateslungcancergrowthandprogression |